ScreenerHero

JBIO Jade Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · jadebiosciences.com
13.77USD+2.68%Mkt Cap: 875.74M $P/E: —

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to bl…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap875.74M USD
Enterprise Value393.03M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-127.41M USD
Revenue/Share—
Last Price13.77 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees55
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.04
PEG—
EV/EBITDA-2.39
EV/Revenue—
P/S—
P/B1.94
EPS (TTM)-1.83
EPS (Forward)-2.66
52W Range
7.69430% of range28.00
52W High28.00 USD
52W Low7.694 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-38.32%
ROA-36.43%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-94.69M USD
CapEx (TTM)196.00K USD
FCF Margin—
FCF Yield—
Net Debt-459.82M USD
Net Debt/EBITDA2.79
Balance Sheet
Debt/Equity0.00
Current Ratio14.93
Quick Ratio14.61
Book Value/Sh6.92 USD
Cash/Share7.25 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateApr 28, 2025
Splits
Last Split1:35
Split DateApr 29, 2025
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)50.13 USD
Upside (mean)+264.0%
Target Range40.00 USD – 77.00 USD
40.00+264.0% to mean77.00
# Analysts8
Ownership
Shares Out.63.60M
Float51.97M
Insiders0.79%
Institutions116.10%
Short Interest
Short Ratio14.2d
Short % Float21.13%
Short % Out.17.27%
Shares Short10.98M
Short (prev mo.)9.65M
Technical
SMA 5019.34 (-28.8%)
SMA 20018.32 (-24.8%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)902.04K
Avg Vol (10d)863.13K
Technical Indicators
RSI (14)25.8
MACD-1.7264
MACD Signal-1.6601
MACD Hist.-0.0663
BB Upper20.02 USD
BB Middle15.86 USD
BB Lower11.69 USD
BB Width52.56%
ATR (14)1.100 USD
Vol Ratio (20d)0.92x